Released Nov 7, 2017, after the close
10-Q filed Nov 8, 2017, 39 days after period end · 0001493152-17-012607
Q3 2017 · 10-Q
Revenue$5.20M$5.20M −4.5% vs Q3 2016−6.3% vs Q2 2017
Net Income-$184.00K-$184.00K N/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.07-$0.07 N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$53,000N/M
Operating Cash Flowderived-$1,750,000N/M
Free Cash Flowderived-$1,973,000N/M
Margins · derived
Operating margin-1.0%+6.6 pt vs Q3 2016
Net margin-3.5%+7.0 pt vs Q3 2016
What the release said
The release
Same quarter
| Metric | Q3 2017 | Q3 2016 | Q3 2015 | Q3 2014 |
|---|---|---|---|---|
| Revenue | $5.20M | $5.44M | $6.08M | $6.01M |
| Net Income | -$184.00K | -$573.00K | -$1.35M | -$1.32M |
| EPS Diluted | -$0.07 | -$0.31 | -$0.73 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR